Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Classical hematology 1

Conditions

Myelodysplastic Syndromes 3Leukemia, Myelomonocytic, Chronic 3Leukemia 3Anemia, Refractory, with Excess of Blasts 3Leukemia, Myeloid, Accelerated Phase 2Blast Crisis 2Neutropenia 1Leukemia, Myeloid, Acute 1Anemia, Refractory 1

Interventions

Filgrastim 6pegylated granulocyte colony-stimulating factor 4pegfilgrastim 4Vancomycin 3Etoposide 3Cytarabine 3Cefepime 3Amikacin 3Teicoplanin 2Methotrexate 2Meropenem 2Granulocyte Colony-Stimulating Factor 2Daunorubicin 2Cyclosporine 2Ciprofloxacin 2Ceftazidime 2ziprasidone 1niraparib 1lintuzumab 1leridistim 1fludarabine phosphate 1angiotensin I (1-7) 1Zolpidem 1Warfarin 1Vitamin B 12 1Vincristine 1Vecuronium Bromide 1Transplantation 1Tranexamic Acid 1Tobramycin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neutropenia × lintuzumab × Classical hematology × Clear all
NCT00002800 2013-07-03

Chemotherapy in Treating Patients With Newly Diagnosed Acute or Chronic Myelogenous Leukemia or Myelodysplastic Syndrome

Memorial Sloan Kettering Cancer Center

Phase 2 Completed
60 enrolled
Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Blast Crisis, Leukemia, Myelodysplastic Syndromes, Neutropenia, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myelomonocytic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡